Press

Successful exit for HTGF: Novo Nordisk to acquire Cardior Pharmaceuticals

March 25, 2024

  • Novo Nordisk will acquire Cardior for up to 1.025 billion Euros in upfront and potential milestone payments.
  • Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart.
  • High-Tech Gründerfonds (HTGF), one of Europe’s leading seed investors, participated in the first financing round in 2017.

Bonn, Germany, 25 March 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved. As part of the deal, HTGF, one of Europe’s leading seed investors, will sell its shares.

The acquisition of Cardior by Novo Nordisk is the next billion-dollar total potential consideration in HTGF’s pharmaceutical portfolio and underscores its strong position in seed financing for life science companies. HTGF participated in the first financing round in 2017. At this early stage, HTGF believed in the team’s vision and the potential of RNA technology.

Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive non-coding RNAs as a platform for addressing root causes of cardiac dysfunctions with an aim to achieve lasting patient impact.

The agreement includes Cardior’s lead compound CDR132L, currently in phase 2 clinical development for the treatment of heart failure. CDR132L is designed to halt and partially reverse cellular pathology by selectively blocking abnormal levels of the microRNA molecule miR-132, potentially leading to long lasting improvement in heart function. In a phase 1b trial published in the European Heart Journal, CDR132L was reported to be safe and well tolerated and the results suggested cardiac functional improvements in people with heart failure compared to placebo. CDR132L is currently being investigated in the phase 2 trial HF-REVERT in 280 people with heart failure with reduced ejection fraction (HFrEF) who have previously suffered a heart attack (myocardial infarction).

“This acquisition is a reflection of CDR132L’s transformative potential as a disease-modifying therapy for heart failure,” said Claudia Ulbrich, MD, CEO and co-founder of Cardior. “Novo Nordisk is the ideal partner based on its deep clinical and commercial expertise combined with its resources to accelerate our late-stage development programme, including through larger registrational studies. We look forward to advancing CDR132L towards market approval.”

Dr Frank Hensel, Principal at HTGF, comments: “Cardior’s success story shows that excellent research conducted in Germany is on an international level. This gives further momentum and visibility to the German biotech environment. We are thrilled to have Novo Nordisk as an excellent partner for Cardior and congratulate the whole team at Cardior on this great success.”

Dr Bernd Goergen, Partner at HTGF, adds: “Cardior’s development is a textbook case for start-ups: a disruptive therapy concept surrounded by experience, support, and a shared, bold vision of everyone involved. We at HTGF are happy to have been a part of it.”

The closing of the acquisition is subject to receipt of applicable regulatory approvals and other customary conditions and is expected to happen in the second quarter of 2024.

Co-founders of Cardior Pharmaceuticals: Claudia Ulbrich, MD. and Prof. Thomas Thum, MD., PhD. (Picture: Cardior Pharmaceuticals)

About High-Tech Gründerfonds  
The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise, entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 180 companies.
Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Media contact
High-Tech Gründerfonds Management GmbH
Tobias Jacob, Senior Marketing & Communications Manager 
T.: +49 228 – 82300 – 121
t.jacob@htgf.de

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

More Press posts

Press
11. April 2024

Scavenger AI secures €1.1m pre-seed funding for data-driven decision making 

The AI start-up helps companies to use their data to make the best possible decision under any circumstances.  Scavenger AI receives € 1.1 million from High-Tech Gründerfonds (HTGF), Calm/Storm Ventures, Femventix and the B4i Investment Fund.  The new capital will be used to launch the first version of the software on the market and serve customers on the waiting list.   Frankfurt, 8 April 2024 – The German data analytics & AI start-up
 
Press
10. April 2024

Proxima Fusion Raises €20M Seed to Accelerate Timeline to Fusion Power

Less than one year from its €7.5M pre-seed round, the first Max Planck fusion spin-out has delivered on its vision of simulation-enabled stellarator design. New funding supports expansion of the world-class team in Munich and its public-private partnerships in Europe to build on existing momentum. Proxima Fusion directly builds on €1.3B of public investment in the ground-breaking W7-X experiment in Germany. Munich, Germany, April 10, 2024 – Proxima Fusion, the first spi
 
Press
9. April 2024

Change in the management of High-Tech Gründerfonds

Bonn, Germany, 9 April 2024 – Guido Schlitzer, responsible for finance, controlling, IT and fund administration on the management board of High-Tech Gründerfonds (HTGF), will leave the seed investor at his own request on 31 December 2024 to pursue new professional challenges. Guido Schlitzer, whom we greatly value both professionally and personally, has provided significant impetus for both HTGF and the start-up ecosystem in Germany over the course of his long career. We very much